Qrxpharma

qrxpharma limited (asx: qrx and otcqx: qrxpy) is a specialty pharmaceutical company and has been focused on the development and commercialisation of new treatments for pain management and abuse prevention products. the company’s dual opioid® platform technology – a patented fixed-ratio combination of morphine and oxycodone – provides effective analgesia with the potential to decrease clinically important opioid-related side effects, in particular respiratory depression. qrxpharma has four complementary pain management product formulations in late and early stage clinical development including: moxduo® ir, an immediate release oral capsule for acute pain; an abuse deterrent formulation of moxduo ir®, moxduo® cr, a controlled release oral tablet (with abuse deterrent and tamper resistant technologies) for chronic pain; and moxduo® iv, an intravenous formulation for moderate to severe hospital-based pain. on 14 august 2014 the company announced that it is halting all further development w